YHYoshio Hirayasu

Yoshio Hirayasu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yoshio Hirayasu has a total of 164 co-authors. Here are the top co-authors by number of shared publications:

  • Tomio Inoue

    Department of Radiology, Yokohama City University School of Medicine, Yokohama, Japan

    5 shared publications
  • Fumi Hayano

    Department of Psychiatry, Yokohama City University School of Medicine, Yokohama, Japan

    4 shared publications
  • Takeshi Asami

    Department of Psychiatry, Yokohama City University School of Medicine, Yokohama, Japan

    4 shared publications
  • Toshinari Odawara

    Yokohama City University Graduate shool of medicine, Department of Psychiatry, Yokohama, Kanagawa, Japan; Yokohama City University Health Management Center, Yokohama, Kanagawa, Japan

    4 shared publications
  • Akira Suda

    Department of Psychiatry, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan

    3 shared publications
  • Chiaki Kawanishi

    Department of Psychiatry, Yokohama City University School of Medicine, Yokohama, Japan

    3 shared publications

Latest Publications

  • Associations of ABCB1 gene polymorphisms with aripiprazole-induced autonomic nervous system dysfunction in schizophrenia

    by Saki Hattori, Akira Suda, Ikuko Kishida, Masatoshi Miyauchi, Yohko Shiraishi, Mami Fujibayashi, Natsuki Tsujita, Chie Ishii, Norio Ishii, Toshio Moritani, et al.


  • Effects of four atypical antipsychotics on autonomic nervous system activity in schizophrenia

    by Saki Hattori, Ikuko Kishida, Akira Suda, Masatoshi Miyauchi, Yohko Shiraishi, Mami Fujibayashi, Natsuki Tsujita, Chie Ishii, Norio Ishii, Toshio Moritani, et al.


  • Open Access

    Voxel-wise correlations between cognition and cerebral blood flow using arterial spin-labeled perfusion MRI in patients with Alzheimer’s disease: a cross-sectional study

    by Tomohiro Kaneta, Omi Katsuse, Takamasa Hirano, Matsuyoshi Ogawa, Ayako Shihikura-Hino, Keisuke Yoshida, Toshinari Odawara, Yoshio Hirayasu, Tomio Inoue

    To analyze voxel-wise correlation between cerebral blood flow (CBF) measured using ASL-MRI and cognition in patients with Alzheimer’s disease (AD). Forty-one patients diagnosed with AD or mild cognitive impairment due to AD were recruited for this study. CBF images were obtained using ASL-MRI (n = 41) with a post-labeling delay (PLD) of 1.5 and 2.5 s (PLD1.5 and PLD2.5, respectively) using a 3 T scanner, in addition to brain perfusion SPECT with N-isopropyl-4-[I-123]iodoamphetamine (n = 28). Voxel-based analyses were performed for ASL-MRI and SPECT using Mini-Mental State Examination (MMSE) scores as covariates. Differences in CBF between PLD1.5 and PLD2.5 were assessed using a paired t-test with SPM12. Significant positive correlations were observed between MMSE scores and CBF at PLD1.5 in the right posterior cingulate cortex (PCC), and both temporo-parietal association cortexes. At PLD2.5, significant positive correlations were determined for MMSE scores and CBF in the superior parietal lobule and the right temporo-parietal association cortex. SPECT showed significant positive correlations in the PCC and both temporo-parietal association cortexes (right-side dominant). PLD1.5 showed significantly higher CBF than PLD2.5 in the proximal areas of vascular territories of the anterior, middle, and posterior cerebral arteries. Significant positive correlations in CBF, measured with both ASL-MRI and SPECT, with cognition were found in the PCC and temporo-parietal association cortexes. PLD1.5 and PLD2.5 showed similar correlations with cognition, although the CBF images had significant differences.


  • A large-scale survey of inpatient suicides: comparison between medical and psychiatric settings

    by Keisuke Inoue, Chiaki Kawanishi, Kotaro Otsuka, Yoshinori Cho, Masaki Shiraishi, Takao Ishii, Hideki Onishi, Yoshio Hirayasu


  • Open Access

    Efficacy and Safety of Bitopertin in Patients with Schizophrenia and Predominant Negative Symptoms: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 2 Trial

    by Yoshio Hirayasu, Shin-Ichi Sato, Norifumi Shuto, Miwa Nakano, Teruhiko Higuchi

    The aim of the present study was to perform a subgroup analysis of data from a phase II global, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of bitopertin, a glycine reuptake inhibitor that activates N-methyl-D-aspartate receptors by increasing the concentration of glycine in the synaptic cleft, in Japanese and non-Japanese patients with schizophrenia and predominant negative symptoms. Patients with schizophrenia and predominant negative symptoms on one or two antipsychotic drugs, including atypical antipsychotic drugs (olanzapine, risperidone, quetiapine, aripiprazole, and paliperidone) as the primary treatment, received bitopertin (10, 30, or 60 mg/day) or placebo once daily for 8 weeks as an add-on treatment. Efficacy was assessed using the Positive and Negative Syndrome Scale (PANSS) negative symptom factor score (NSFS). The efficacy of bitopertin (10 mg and 30 mg) was similar between Japanese and non-Japanese patients. In the bitopertin 60-mg group, no difference from the placebo group was observed in Japanese or non-Japanese patients. The response to placebo was lower in Japanese patients, and there was a trend towards a greater difference in the change in PANSS NSFS between the placebo group and the 10-mg and 30-mg groups among Japanese patients. The safety profile of bitopertin was favorable in Japanese and non-Japanese patients. According to this subgroup analysis from a global phase II study of bitopertin, there was no difference in terms of efficacy and safety between Japanese and non-Japanese patients.


  • Open Access

    A double-blind randomized study assessing safety and efficacy following one-year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, in Japanese patients with schizophrenia

    by Yoshio Hirayasu, Shin-Ichi Sato, Hideaki Takahashi, Sayaka Iida, Norifumi Shuto, Seitaro Yoshida, Takashi Funatogawa, Takahito Yamada, Teruhiko Higuchi

    Bitopertin, a glycine reuptake inhibitor, was investigated as a novel treatment for schizophrenia. We report all the results of a double-blind randomized study assessing safety and efficacy following 52-week adjunctive treatment with bitopertin in Japanese patients with schizophrenia. This study enrolled Japanese outpatients with schizophrenia who met criteria for either “negative symptoms”, i.e., patients with persistent, predominant negative symptoms of schizophrenia even after long-term treatment with antipsychotics or “sub-optimally controlled symptoms”, i.e., patients with insufficiently improved symptoms of schizophrenia even after long-term treatment with antipsychotics, respectively. One hundred sixty-one patients were randomly assigned to receive 52-week treatments with bitopertin doses of 5, 10, or 20 mg/day at ratio of 1:5:5, where existing antipsychotics were concomitantly administered. Efficacy endpoints included Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression (CGI), and Personal and Social Performance (PSP). The purpose of the present study is primarily to evaluate the safety, and secondarily to investigate the clinical efficacy of bitopertin. One hundred fourteen patients (71 %) completed 52-week treatment with bitopertin. Most of the adverse events were mild or moderate in their severity. The patients in the 20-mg group experienced more adverse events than the patients in the other two groups. Common dose-dependent adverse events were somnolence and insomnia associated with worsening schizophrenia. The blood hemoglobin levels gradually decreased from baseline in a dose-dependent manner, but there were no patients with the decrease below 10 g/dL that would have led to their discontinuation. All the efficacy endpoints gradually improved in all the treatment groups for both of the two symptoms, while there were no clear differences among the three dose groups. Altogether, bitopertin was found to be generally safe and well-tolerated for the treatment of patients with schizophrenia. All three bitopertin treated groups showed improvements in all the efficacy endpoints for both of the two symptoms, i.e., “negative symptoms” and “sub-optimally controlled symptoms”, throughout the duration of the study. Japan Pharmaceutical Information Center, number JapicCTI-111627 (registered on September 20, 2011)


  • Open Access

    Effects of NRG1 genotypes on orbitofrontal sulcogyral patterns in Japanese patients diagnosed with schizophrenia

    by Asuka Yoshimi, Akira Suda, Fumi Hayano, Motoaki Nakamura, Kumi Aoyama‐Uehara, Jun Konishi, Takeshi Asami, Ikuko Kishida, Chiaki Kawanishi, Tomio Inoue, et al.

    Aim: Numerous reports have described differences in the distribution of orbitofrontal cortex (OFC) sulcogyral patterns between patients with schizophrenia (SZ patients) and healthy controls (HC). Alterations in OFC morphology are also observed in those at high risk for developing SZ and in first‐episode SZ, suggesting that genetic associations may be extant in determining OFC sulcogyral patterns. We investigated the association between single nucleotide polymorphisms (SNP) in NRG1 and OFC sulcogyral patterns.Methods: A total of 59 Japanese patients diagnosed with SZ and 60 HC were scanned on a 1.5‐T magnet. Patients were also assessed clinically. OFC sulcogyral patterns were evaluated for each participant, and genotyping was performed for four SNP in NRG1 (SNP8NRG243177, SNP8NRG221533, SNP8NRG241930, and rs1081062).Results: There were significant differences in the distribution of OFC sulcogyral patterns between SZ patients and HC (χ2 = 6.52, P = 0.038). SZ patients showed an increase in the frequency of Type III expression, which was associated with an earlier age of disease onset (β = −0.302, F = 4.948, P = 0.030). Although no difference was found in genotype frequencies between SZ patients and HC, an NRG1 SNP, SNP8NRG243177, was associated with Type II expression in SZ patients (β = 0.237, F = 4.120, P = 0.047).Conclusion: Our results suggest that OFC sulcogyral pattern formation in schizophrenia may be associated with NRG1 allele frequency, which is closely related to neurodevelopment.


  • Neuroplasticity possibly induced by a series of prefrontal rTMS for major depression

    by Motoaki Nakamura, Yoshihiro Noda, Takashi Saeki, Shunsuke Hayasaka, Takuji Izuno, Takuya Yoshiike, Yoshio Hirayasu

  • Structural and functional brain alterations induced by a series of prefrontal repetitive transcranial magnetic stimulation

    by Motoaki Nakamura, Yoshihiro Noda, Takashi Saeki, Shunsuke Hayasaka, Takuji Izuno, Takuya Yoshiike, Yoshio Hirayasu

  • Association of the five‐factor personality model with prefrontal activation during frontal lobe task performance using two‐channel near‐infrared spectroscopy

    by Haruka Ikeda, Eiji Ikeda, Kazumasa Shiozaki, Yoshio Hirayasu

    Aim: The aim of this study was to investigate the biological background of the five‐factor model using near‐infrared spectroscopy and cognitive tasks.Methods: Twenty right‐handed healthy volunteers participated in this study. Their personality traits were assessed using the NEO Five‐Factor Inventory, and changes in oxyhemoglobin concentration ([oxy‐Hb]) were measured during cognitive tasks using a wireless near‐infrared spectroscopy.Results: The average [oxy‐Hb] in the right prefrontal area had a significant positive correlation with the agreeableness score during the Stroop test at incongruent stimulus block. For the verbal fluency task, there were no significant correlations of bilateral [oxy‐Hb] changes with any items.Conclusion: Higher agreeableness scores may involve less suppression to the default mode network related to resting state brain function. Keeping selective attention during the Stroop test may require more power of concentration than retrieving words during the verbal fluency task.